Xencor, Inc. (XNCR)Healthcare | Biotechnology | Pasadena, United States | NasdaqGM
14.96 USD
-0.89
(-5.615%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 14.96 |
Hot Take ↕ | July 11, 2026, 6:05 a.m. EDT
The investment case for Xencor is currently broken by a catastrophic failure in its multi-year price trajectory. The stock has suffered a 54% drop in the trailing twelve months and sits in the middle of four consecutive years of negative annual returns, a pattern that defines a structural decline rather than a temporary setback. While the balance sheet appears robust with a current ratio of 6.57 and manageable debt relative to cash, the market has priced out the business entirely, evidenced by the negative forward P/E and massive short interest. The disconnect between the 'strong buy' analyst consensus and the reality of the stock's performance is stark; analysts are likely looking at pipeline potential that the market has already deemed insufficient to overcome the execution risks highlighted in recent downgrades. Options flow confirms this pessimism, with traders aggressively buying insurance at deep out-of-the-money strikes while offering almost no leverage for upside. Until there is concrete evidence of revenue recovery or a definitive clinical milestone that shifts the narrative, the risk-reward profile remains skewed heavily against the buyer. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.106832 |
| AutoETS | 0.107408 |
| AutoTheta | 0.108868 |
| MSTL | 0.110439 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 2.66 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.110 |
| Excess Kurtosis | -0.96 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 33.971 |
| Revenue per Share | 1.304 |
| Market Cap | 1,109,158,400 |
| Forward P/E | -4.22 |
| Beta | 0.86 |
| Profit Margins | -177.10% |
| Website | https://www.xencor.com |
As of July 11, 2026, 6:05 a.m. EDT: Speculators are positioned defensively with heavy put volume and open interest at strikes significantly below the current price (e.g., $10 and $12.50 expiring in November), while call activity remains sparse and concentrated near-the-money. Implied volatility is elevated on downside protection, suggesting a market expectation of further weakness rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.79096043 |
| Address1 | 465 North Halstead Street |
| Address2 | Suite 200 |
| All Time High | 58.345 |
| All Time Low | 5.75 |
| Ask | 18.84 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 1,058,170 |
| Average Daily Volume3 Month | 831,631 |
| Average Volume | 831,631 |
| Average Volume10Days | 1,058,170 |
| Beta | 0.863 |
| Bid | 10.99 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 6.962 |
| City | Pasadena |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 14.96 |
| Current Ratio | 6.573 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 15.53 |
| Day Low | 14.67 |
| Debt To Equity | 33.971 |
| Display Name | Xencor |
| Earnings Timestamp | 1,778,097,600 |
| Earnings Timestamp End | 1,785,960,000 |
| Earnings Timestamp Start | 1,785,960,000 |
| Ebitda | -201,795,008 |
| Ebitda Margins | -2.07267 |
| Enterprise To Ebitda | -4.16 |
| Enterprise To Revenue | 8.621 |
| Enterprise Value | 839,372,288 |
| Eps Current Year | -4.02601 |
| Eps Forward | -3.54774 |
| Eps Trailing Twelve Months | -2.29 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 12.8979 |
| Fifty Day Average Change | 2.0621004 |
| Fifty Day Average Change Percent | 0.15987878 |
| Fifty Two Week Change Percent | 79.09605 |
| Fifty Two Week High | 18.69 |
| Fifty Two Week High Change | -3.7300005 |
| Fifty Two Week High Change Percent | -0.19957198 |
| Fifty Two Week Low | 6.92 |
| Fifty Two Week Low Change | 8.04 |
| Fifty Two Week Low Change Percent | 1.1618497 |
| Fifty Two Week Range | 6.92 - 18.69 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,386,081,000,000 |
| Float Shares | 54,417,707 |
| Forward Eps | -3.54774 |
| Forward P E | -4.216769 |
| Free Cashflow | -76,885,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 260 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | -1.52183 |
| Gross Profits | -148,164,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01223 |
| Held Percent Institutions | 1.1539 |
| Implied Shares Outstanding | 74,141,596 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California. |
| Long Name | Xencor, Inc. |
| Market | us_market |
| Market Cap | 1,109,158,400 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_744102 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -172,420,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,175,885,712 |
| Number Of Analyst Opinions | 12 |
| Open | 15.53 |
| Operating Cashflow | -186,524,992 |
| Operating Margins | -17.24136 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 626 305 5900 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 14.96 |
| Post Market Time | 1,783,981,120 |
| Previous Close | 15.85 |
| Price Eps Current Year | -3.7158377 |
| Price Hint | 2 |
| Price To Book | 2.1488078 |
| Price To Sales Trailing12 Months | 11.392342 |
| Profit Margins | -1.77096 |
| Quick Ratio | 6.221 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -0.89 |
| Regular Market Change Percent | -5.61514 |
| Regular Market Day High | 15.53 |
| Regular Market Day Low | 14.67 |
| Regular Market Day Range | 14.67 - 15.53 |
| Regular Market Open | 15.53 |
| Regular Market Previous Close | 15.85 |
| Regular Market Price | 14.96 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 649,781 |
| Return On Assets | -0.16157 |
| Return On Equity | -0.29843 |
| Revenue Growth | -0.862 |
| Revenue Per Share | 1.304 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 74,141,596 |
| Shares Percent Shares Out | 0.1552 |
| Shares Short | 11,506,336 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 10,900,110 |
| Short Name | Xencor, Inc. |
| Short Percent Of Float | 0.2204 |
| Short Ratio | 12.14 |
| Source Interval | 15 |
| State | CA |
| Symbol | XNCR |
| Target High Price | 43.0 |
| Target Low Price | 14.0 |
| Target Mean Price | 28.33333 |
| Target Median Price | 27.0 |
| Total Cash | 444,950,016 |
| Total Cash Per Share | 6.001 |
| Total Debt | 175,164,000 |
| Total Revenue | 97,360,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.29 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 13.3148 |
| Two Hundred Day Average Change | 1.6451998 |
| Two Hundred Day Average Change Percent | 0.12356173 |
| Type Disp | Equity |
| Volume | 649,781 |
| Website | https://www.xencor.com |
| Zip | 91,107 |